Truist analyst David MacDonald lowered the firm’s price target on Molina Healthcare to $380 from $400 but keeps a Buy rating on the shares after its Q4 results. The company has had a solid finish to 2022 marked by membership, revenue, MCR and adjusted EPS all better than the firm’s expectations, though its price target cut reflects more recent market multiples, the analyst tells investors in a research note.
Published first on TheFly
See the top stocks recommended by analysts >>
Read More on MOH:
- Molina Healthcare sees FY23 adjusted EPS at least $19.75, consensus $19.59
- Molina Healthcare reports Q4 adjusted EPS $4.10, consensus $4.02
- Molina Healthcare price target lowered to $375 from $400 at Barclays
- Molina Healthcare to double California revenue with Medi-Cal contracts in 2024
- Molina Healthcare to record $200M impairment charge in Q4 on leased space
